先天性代謝異常症用医療食品の世界市場インサイト、2029年までの予測

Global Medical Foods for Inborn Errors of Metabolism Market Insights, Forecast to 2029

食事療法は、先天性代謝異常の伝統的な方法である。医療用食品とは、医師の指導のもと、特定の病気や症状の食事管理を目的として作られた特殊な食品です。先天性代謝異常とは、代謝に関わるタンパク質をコードす... もっと見る

foods

出版社	出版年月	電子版価格	言語
QYResearch QYリサーチ	2023年5月2日	US$4,900 シングルユーザライセンスライセンス・価格情報注文方法はこちら	英語

※当ページの内容はウェブ更新時の情報です。
最新版の価格やページ数などの情報についてはお問合せください。
日本語のページは自動翻訳を利用し作成しています。
実際のレポートは英文のみでご納品いたします。

サマリー

食事療法は、先天性代謝異常の伝統的な方法である。医療用食品とは、医師の指導のもと、特定の病気や症状の食事管理を目的として作られた特殊な食品です。先天性代謝異常とは、代謝に関わるタンパク質をコードする遺伝子の変異による先天的な障害を指す。先天性代謝異常症は、異質な疾患群であり、自然変異により遺伝する可能性が高い。この疾患は通常、炭水化物、タンパク質、脂肪酸などの生体分子の分解または貯蔵に関与する代謝経路の失敗を伴う。

先天性代謝異常症向け医療用食品の世界市場は、2023年の100万米ドルから2029年には100万米ドルに達し、予測期間中の複合年間成長率（CAGR）は％と予測されています。
先天性代謝異常症向け医療用食品の米国・カナダ市場は、2023年の100万ドルから2029年には100万ドルに達すると予測され、2023年から2029年の予測期間中にCAGR %で増加すると予測されます。
先天性代謝異常症用医療食品の中国市場は、2023年の100万ドルから2029年には100万ドルに達すると推定され、2023年から2029年の予測期間中に年平均成長率は%になると予測されます。
先天性代謝異常症用医療食品のヨーロッパ市場は、2023年の100万ドルから2029年には100万ドルに達すると推定され、2023年から2029年の予測期間中にCAGR %で増加すると予測されます。
先天性代謝異常症用医療食品の世界の主要メーカーは、ネスレ、アボット、レキットベンキーザーグループ、味の素、Solace Nutrition、Primus Pharmaceuticals、BioMarin Pharmaceutical、Danone SAおよびGalen Limitedなどです。2022年、世界の上位5社は、売上高で約 %のシェアを占めています。

レポートには、以下の内容が含まれています：
本レポートでは、先天性代謝異常症向け医療用食品の世界市場の概要、売上、収益、価格などを紹介しています。2018年～2022年の歴史的な市場収益/売上データ、2023年の予測、2029年までのCAGRの予測など、世界市場動向の分析が可能です。
本レポートでは、先天性代謝異常症用メディカルフーズの主要生産者を調査し、主要地域や国の売上も掲載しています。先天性代謝異常用医療食品の今後の市場可能性のハイライトと、この市場を様々なセグメントとサブセグメントに分けて予測するための主要地域/国への注目点です。米国、カナダ、メキシコ、ブラジル、中国、日本、韓国、東南アジア、インド、ドイツ、英国、イタリア、中東、アフリカ、その他の国々の国別データおよび市場価値分析。

本レポートでは、2018年から2023年のデータをもとに、主要メーカーの先天性代謝異常用医療食品の売上、収益、市場シェア、業界ランキングに焦点を当てています。世界の先天性代謝異常用医療食品市場における主要なステークホルダーを特定し、その競争環境と市場ポジショニングを最近の動向とセグメント別の収益に基づき分析します。本レポートは、関係者が競争環境を理解し、より多くの洞察を得て、より良い方法で事業と市場戦略を位置づけるのに役立ちます。
本レポートでは、2018年から2029年までの、タイプ別、用途別のセグメントデータ、売上、収益、価格を分析しています。先天性代謝異常症用医療食品の売上、予測される成長動向、生産技術、用途、エンドユーザー産業の評価と市場規模の予測。
ネスレ、アボット、レキットベンキーザーグループ、味の素、ソラスニュートリション、プリムス製薬、バイオマリン製薬、ダノンSA、ガレンリミテッドなど、世界の主要企業の説明的な企業プロフィール。

会社別
ネスレ
アボット
レキットベンキーザーグループ
味の素
ソレイユニュートリション
プリムスファーマシューティカルズ
バイオマリン・ファーマシューティカル
ダノンSA
ガレン・リミテッド
PKU-MDMIL
タイプ別セグメント
アミノ酸
GMP含有グリタクチン
鉄分入りアミノ酸調整済み乳児用調製粉乳
低タンパク質食品
その他
アプリケーション別セグメント
フェニルケトン尿症(PKU)
メイプルシロップ尿症（MSUD）
尿素サイクル障害
腎臓病
その他
地域別セグメント
アメリカ・カナダ
U.S.
カナダ
中国
アジア（中国を除く）
日本
南朝鮮
中国台湾
東南アジア
インド
ヨーロッパ
ドイツ
フランス
イギリス
イタリア
ロシア
中近東、アフリカ、中南米
ブラジル
メキシコ
トルコ
イスラエル
GCC諸国

章立て
第1章：報告書のスコープ、市場セグメント別（タイプ別、用途別など）のエグゼクティブサマリー、各市場セグメントの市場規模、将来の発展可能性などを紹介。市場の現状と、短中期および長期的にどのような進化を遂げる可能性があるのかについて、ハイレベルな視点で解説しています。
第2章先天性代謝異常症用医療食品の世界、地域レベル、国レベルでの販売（消費）、収益。各地域とその主要国の市場規模と発展可能性を定量的に分析し、世界各国の市場発展、将来の発展見通し、市場スペース、生産能力などを紹介しています。
第3章：先天性代謝異常用医療食品メーカーの競争環境、価格、売上、収益、市場シェア、業界ランキング、最新の開発計画、M&A情報などを詳細に分析。
第4章：タイプ別の様々な市場セグメントの分析を提供し、各市場セグメントの売上高、収益、平均価格、開発可能性をカバーし、読者が異なる市場セグメントでブルーオーシャン市場を見つけるのを助ける。
第5章：読者が異なる下流市場でブルーオーシャン市場を見つけるのを助けるために、各市場セグメントの売上高、収益、平均価格、および開発可能性をカバーする、様々な市場セグメントのアプリケーションの分析を提供します。
第6章：米国とカナダ（US & Canada）タイプ別、アプリケーション別、国別、各セグメント別の売上と収益。
第7章：ヨーロッパ（Europe）：タイプ別、アプリケーション別、国別、セグメント別の売上高と収益。
第8章：中国種類別、用途別、国別、各セグメント別の売上と収益。
第9章：アジア（中国を除く）タイプ別、アプリケーション別、地域別、各セグメント別の売上と収益。
第10章：中東、アフリカ、中南米：タイプ別、アプリケーション別、国別、各セグメント別の売上と収益。
第11章：主要メーカーのプロファイルを提供し、製品の説明と仕様、先天性代謝異常用医療食品の売上、収益、価格、粗利益率、最近の開発など、市場の主要企業の基本状況を詳細に紹介する。
第12章：産業チェーン、販売チャネル、主要原材料、流通業者、顧客に関する分析。
第13章：市場力学、市場の最新動向、市場の推進要因と制限要因、業界のメーカーが直面する課題とリスク、業界の関連政策の分析を紹介する。
第14章：本レポートの要点と結論。

ページTOPに戻る

1 Study Coverage
1.1 Medical Foods for Inborn Errors of Metabolism Product Introduction
1.2 Market by Type
1.2.1 Global Medical Foods for Inborn Errors of Metabolism Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Amino Acid
1.2.3 Glytactin with GMP
1.2.4 Amino Acid-Modified Infant Formula With Iron
1.2.5 Low Protein Food
1.2.6 Others
1.3 Market by Application
1.3.1 Global Medical Foods for Inborn Errors of Metabolism Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Phenylketonuria (PKU)
1.3.3 Maple Syrup Urine Disease (MSUD)
1.3.4 Urea Cycle Disorders
1.3.5 Renal Disease
1.3.6 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Medical Foods for Inborn Errors of Metabolism Sales Estimates and Forecasts 2018-2029
2.2 Global Medical Foods for Inborn Errors of Metabolism Revenue by Region
2.2.1 Global Medical Foods for Inborn Errors of Metabolism Revenue by Region: 2018 VS 2022 VS 2029
2.2.2 Global Medical Foods for Inborn Errors of Metabolism Revenue by Region (2018-2023)
2.2.3 Global Medical Foods for Inborn Errors of Metabolism Revenue by Region (2024-2029)
2.2.4 Global Medical Foods for Inborn Errors of Metabolism Revenue Market Share by Region (2018-2029)
2.3 Global Medical Foods for Inborn Errors of Metabolism Sales Estimates and Forecasts 2018-2029
2.4 Global Medical Foods for Inborn Errors of Metabolism Sales by Region
2.4.1 Global Medical Foods for Inborn Errors of Metabolism Sales by Region: 2018 VS 2022 VS 2029
2.4.2 Global Medical Foods for Inborn Errors of Metabolism Sales by Region (2018-2023)
2.4.3 Global Medical Foods for Inborn Errors of Metabolism Sales by Region (2024-2029)
2.4.4 Global Medical Foods for Inborn Errors of Metabolism Sales Market Share by Region (2018-2029)
2.5 US & Canada
2.6 Europe
2.7 China
2.8 Asia (excluding China)
2.9 Middle East, Africa and Latin America
3 Competition by Manufactures
3.1 Global Medical Foods for Inborn Errors of Metabolism Sales by Manufacturers
3.1.1 Global Medical Foods for Inborn Errors of Metabolism Sales by Manufacturers (2018-2023)
3.1.2 Global Medical Foods for Inborn Errors of Metabolism Sales Market Share by Manufacturers (2018-2023)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Medical Foods for Inborn Errors of Metabolism in 2022
3.2 Global Medical Foods for Inborn Errors of Metabolism Revenue by Manufacturers
3.2.1 Global Medical Foods for Inborn Errors of Metabolism Revenue by Manufacturers (2018-2023)
3.2.2 Global Medical Foods for Inborn Errors of Metabolism Revenue Market Share by Manufacturers (2018-2023)
3.2.3 Global Top 10 and Top 5 Companies by Medical Foods for Inborn Errors of Metabolism Revenue in 2022
3.3 Global Key Players of Medical Foods for Inborn Errors of Metabolism, Industry Ranking, 2021 VS 2022 VS 2023
3.4 Global Medical Foods for Inborn Errors of Metabolism Sales Price by Manufacturers
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Medical Foods for Inborn Errors of Metabolism Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Medical Foods for Inborn Errors of Metabolism, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Medical Foods for Inborn Errors of Metabolism, Product Offered and Application
3.8 Global Key Manufacturers of Medical Foods for Inborn Errors of Metabolism, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Medical Foods for Inborn Errors of Metabolism Sales by Type
4.1.1 Global Medical Foods for Inborn Errors of Metabolism Historical Sales by Type (2018-2023)
4.1.2 Global Medical Foods for Inborn Errors of Metabolism Forecasted Sales by Type (2024-2029)
4.1.3 Global Medical Foods for Inborn Errors of Metabolism Sales Market Share by Type (2018-2029)
4.2 Global Medical Foods for Inborn Errors of Metabolism Revenue by Type
4.2.1 Global Medical Foods for Inborn Errors of Metabolism Historical Revenue by Type (2018-2023)
4.2.2 Global Medical Foods for Inborn Errors of Metabolism Forecasted Revenue by Type (2024-2029)
4.2.3 Global Medical Foods for Inborn Errors of Metabolism Revenue Market Share by Type (2018-2029)
4.3 Global Medical Foods for Inborn Errors of Metabolism Price by Type
4.3.1 Global Medical Foods for Inborn Errors of Metabolism Price by Type (2018-2023)
4.3.2 Global Medical Foods for Inborn Errors of Metabolism Price Forecast by Type (2024-2029)
5 Market Size by Application
5.1 Global Medical Foods for Inborn Errors of Metabolism Sales by Application
5.1.1 Global Medical Foods for Inborn Errors of Metabolism Historical Sales by Application (2018-2023)
5.1.2 Global Medical Foods for Inborn Errors of Metabolism Forecasted Sales by Application (2024-2029)
5.1.3 Global Medical Foods for Inborn Errors of Metabolism Sales Market Share by Application (2018-2029)
5.2 Global Medical Foods for Inborn Errors of Metabolism Revenue by Application
5.2.1 Global Medical Foods for Inborn Errors of Metabolism Historical Revenue by Application (2018-2023)
5.2.2 Global Medical Foods for Inborn Errors of Metabolism Forecasted Revenue by Application (2024-2029)
5.2.3 Global Medical Foods for Inborn Errors of Metabolism Revenue Market Share by Application (2018-2029)
5.3 Global Medical Foods for Inborn Errors of Metabolism Price by Application
5.3.1 Global Medical Foods for Inborn Errors of Metabolism Price by Application (2018-2023)
5.3.2 Global Medical Foods for Inborn Errors of Metabolism Price Forecast by Application (2024-2029)
6 US & Canada
6.1 US & Canada Medical Foods for Inborn Errors of Metabolism Market Size by Type
6.1.1 US & Canada Medical Foods for Inborn Errors of Metabolism Sales by Type (2018-2029)
6.1.2 US & Canada Medical Foods for Inborn Errors of Metabolism Revenue by Type (2018-2029)
6.2 US & Canada Medical Foods for Inborn Errors of Metabolism Market Size by Application
6.2.1 US & Canada Medical Foods for Inborn Errors of Metabolism Sales by Application (2018-2029)
6.2.2 US & Canada Medical Foods for Inborn Errors of Metabolism Revenue by Application (2018-2029)
6.3 US & Canada Medical Foods for Inborn Errors of Metabolism Market Size by Country
6.3.1 US & Canada Medical Foods for Inborn Errors of Metabolism Revenue by Country: 2018 VS 2022 VS 2029
6.3.2 US & Canada Medical Foods for Inborn Errors of Metabolism Sales by Country (2018-2029)
6.3.3 US & Canada Medical Foods for Inborn Errors of Metabolism Revenue by Country (2018-2029)
6.3.4 US
6.3.5 Canada
7 Europe
7.1 Europe Medical Foods for Inborn Errors of Metabolism Market Size by Type
7.1.1 Europe Medical Foods for Inborn Errors of Metabolism Sales by Type (2018-2029)
7.1.2 Europe Medical Foods for Inborn Errors of Metabolism Revenue by Type (2018-2029)
7.2 Europe Medical Foods for Inborn Errors of Metabolism Market Size by Application
7.2.1 Europe Medical Foods for Inborn Errors of Metabolism Sales by Application (2018-2029)
7.2.2 Europe Medical Foods for Inborn Errors of Metabolism Revenue by Application (2018-2029)
7.3 Europe Medical Foods for Inborn Errors of Metabolism Market Size by Country
7.3.1 Europe Medical Foods for Inborn Errors of Metabolism Revenue by Country: 2018 VS 2022 VS 2029
7.3.2 Europe Medical Foods for Inborn Errors of Metabolism Sales by Country (2018-2029)
7.3.3 Europe Medical Foods for Inborn Errors of Metabolism Revenue by Country (2018-2029)
7.3.4 Germany
7.3.5 France
7.3.6 U.K.
7.3.7 Italy
7.3.8 Russia
8 China
8.1 China Medical Foods for Inborn Errors of Metabolism Market Size
8.1.1 China Medical Foods for Inborn Errors of Metabolism Sales (2018-2029)
8.1.2 China Medical Foods for Inborn Errors of Metabolism Revenue (2018-2029)
8.2 China Medical Foods for Inborn Errors of Metabolism Market Size by Application
8.2.1 China Medical Foods for Inborn Errors of Metabolism Sales by Application (2018-2029)
8.2.2 China Medical Foods for Inborn Errors of Metabolism Revenue by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia Medical Foods for Inborn Errors of Metabolism Market Size by Type
9.1.1 Asia Medical Foods for Inborn Errors of Metabolism Sales by Type (2018-2029)
9.1.2 Asia Medical Foods for Inborn Errors of Metabolism Revenue by Type (2018-2029)
9.2 Asia Medical Foods for Inborn Errors of Metabolism Market Size by Application
9.2.1 Asia Medical Foods for Inborn Errors of Metabolism Sales by Application (2018-2029)
9.2.2 Asia Medical Foods for Inborn Errors of Metabolism Revenue by Application (2018-2029)
9.3 Asia Medical Foods for Inborn Errors of Metabolism Sales by Region
9.3.1 Asia Medical Foods for Inborn Errors of Metabolism Revenue by Region: 2018 VS 2022 VS 2029
9.3.2 Asia Medical Foods for Inborn Errors of Metabolism Revenue by Region (2018-2029)
9.3.3 Asia Medical Foods for Inborn Errors of Metabolism Sales by Region (2018-2029)
9.3.4 Japan
9.3.5 South Korea
9.3.6 China Taiwan
9.3.7 Southeast Asia
9.3.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Medical Foods for Inborn Errors of Metabolism Market Size by Type
10.1.1 Middle East, Africa and Latin America Medical Foods for Inborn Errors of Metabolism Sales by Type (2018-2029)
10.1.2 Middle East, Africa and Latin America Medical Foods for Inborn Errors of Metabolism Revenue by Type (2018-2029)
10.2 Middle East, Africa and Latin America Medical Foods for Inborn Errors of Metabolism Market Size by Application
10.2.1 Middle East, Africa and Latin America Medical Foods for Inborn Errors of Metabolism Sales by Application (2018-2029)
10.2.2 Middle East, Africa and Latin America Medical Foods for Inborn Errors of Metabolism Revenue by Application (2018-2029)
10.3 Middle East, Africa and Latin America Medical Foods for Inborn Errors of Metabolism Sales by Country
10.3.1 Middle East, Africa and Latin America Medical Foods for Inborn Errors of Metabolism Revenue by Country: 2018 VS 2022 VS 2029
10.3.2 Middle East, Africa and Latin America Medical Foods for Inborn Errors of Metabolism Revenue by Country (2018-2029)
10.3.3 Middle East, Africa and Latin America Medical Foods for Inborn Errors of Metabolism Sales by Country (2018-2029)
10.3.4 Brazil
10.3.5 Mexico
10.3.6 Turkey
10.3.7 Israel
10.3.8 GCC Countries
11 Company Profiles
11.1 Nestlé
11.1.1 Nestlé Company Information
11.1.2 Nestlé Overview
11.1.3 Nestlé Medical Foods for Inborn Errors of Metabolism Sales, Price, Revenue and Gross Margin (2018-2023)
11.1.4 Nestlé Medical Foods for Inborn Errors of Metabolism Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Nestlé Recent Developments
11.2 Abbott
11.2.1 Abbott Company Information
11.2.2 Abbott Overview
11.2.3 Abbott Medical Foods for Inborn Errors of Metabolism Sales, Price, Revenue and Gross Margin (2018-2023)
11.2.4 Abbott Medical Foods for Inborn Errors of Metabolism Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Abbott Recent Developments
11.3 Reckitt Benckiser Group
11.3.1 Reckitt Benckiser Group Company Information
11.3.2 Reckitt Benckiser Group Overview
11.3.3 Reckitt Benckiser Group Medical Foods for Inborn Errors of Metabolism Sales, Price, Revenue and Gross Margin (2018-2023)
11.3.4 Reckitt Benckiser Group Medical Foods for Inborn Errors of Metabolism Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Reckitt Benckiser Group Recent Developments
11.4 Ajinomoto
11.4.1 Ajinomoto Company Information
11.4.2 Ajinomoto Overview
11.4.3 Ajinomoto Medical Foods for Inborn Errors of Metabolism Sales, Price, Revenue and Gross Margin (2018-2023)
11.4.4 Ajinomoto Medical Foods for Inborn Errors of Metabolism Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Ajinomoto Recent Developments
11.5 Solace Nutrition
11.5.1 Solace Nutrition Company Information
11.5.2 Solace Nutrition Overview
11.5.3 Solace Nutrition Medical Foods for Inborn Errors of Metabolism Sales, Price, Revenue and Gross Margin (2018-2023)
11.5.4 Solace Nutrition Medical Foods for Inborn Errors of Metabolism Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Solace Nutrition Recent Developments
11.6 Primus Pharmaceuticals
11.6.1 Primus Pharmaceuticals Company Information
11.6.2 Primus Pharmaceuticals Overview
11.6.3 Primus Pharmaceuticals Medical Foods for Inborn Errors of Metabolism Sales, Price, Revenue and Gross Margin (2018-2023)
11.6.4 Primus Pharmaceuticals Medical Foods for Inborn Errors of Metabolism Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Primus Pharmaceuticals Recent Developments
11.7 BioMarin Pharmaceutical
11.7.1 BioMarin Pharmaceutical Company Information
11.7.2 BioMarin Pharmaceutical Overview
11.7.3 BioMarin Pharmaceutical Medical Foods for Inborn Errors of Metabolism Sales, Price, Revenue and Gross Margin (2018-2023)
11.7.4 BioMarin Pharmaceutical Medical Foods for Inborn Errors of Metabolism Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 BioMarin Pharmaceutical Recent Developments
11.8 Danone SA
11.8.1 Danone SA Company Information
11.8.2 Danone SA Overview
11.8.3 Danone SA Medical Foods for Inborn Errors of Metabolism Sales, Price, Revenue and Gross Margin (2018-2023)
11.8.4 Danone SA Medical Foods for Inborn Errors of Metabolism Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Danone SA Recent Developments
11.9 Galen Limited
11.9.1 Galen Limited Company Information
11.9.2 Galen Limited Overview
11.9.3 Galen Limited Medical Foods for Inborn Errors of Metabolism Sales, Price, Revenue and Gross Margin (2018-2023)
11.9.4 Galen Limited Medical Foods for Inborn Errors of Metabolism Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Galen Limited Recent Developments
11.10 PKU-MDMIL
11.10.1 PKU-MDMIL Company Information
11.10.2 PKU-MDMIL Overview
11.10.3 PKU-MDMIL Medical Foods for Inborn Errors of Metabolism Sales, Price, Revenue and Gross Margin (2018-2023)
11.10.4 PKU-MDMIL Medical Foods for Inborn Errors of Metabolism Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 PKU-MDMIL Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Medical Foods for Inborn Errors of Metabolism Industry Chain Analysis
12.2 Medical Foods for Inborn Errors of Metabolism Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Medical Foods for Inborn Errors of Metabolism Production Mode & Process
12.4 Medical Foods for Inborn Errors of Metabolism Sales and Marketing
12.4.1 Medical Foods for Inborn Errors of Metabolism Sales Channels
12.4.2 Medical Foods for Inborn Errors of Metabolism Distributors
12.5 Medical Foods for Inborn Errors of Metabolism Customers
13 Market Dynamics
13.1 Medical Foods for Inborn Errors of Metabolism Industry Trends
13.2 Medical Foods for Inborn Errors of Metabolism Market Drivers
13.3 Medical Foods for Inborn Errors of Metabolism Market Challenges
13.4 Medical Foods for Inborn Errors of Metabolism Market Restraints
14 Key Findings in The Global Medical Foods for Inborn Errors of Metabolism Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

ページTOPに戻る

Table of Contents

Summary

Diet therapy is the traditional method of inborn errors of metabolism. Medical food is the specialized food formulated to be consumed under physician supervision and intended for specific dietary management of a particular disease or condition. Inborn errors of metabolism refer to inherited disorders due to mutation in genes coding for proteins functioning in metabolism. The inborn errors of metabolism are a heterogeneous group of disorders and are likely to be inherited through spontaneous mutation. The diseases usually involve failure of metabolic pathways that are either involved in breakdown or storage of biomolecules, such as carbohydrates, proteins, and fatty acids.

The global Medical Foods for Inborn Errors of Metabolism market is projected to grow from US$ million in 2023 to US$ million by 2029, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Medical Foods for Inborn Errors of Metabolism is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The China market for Medical Foods for Inborn Errors of Metabolism is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The Europe market for Medical Foods for Inborn Errors of Metabolism is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global key manufacturers of Medical Foods for Inborn Errors of Metabolism include Nestlé, Abbott, Reckitt Benckiser Group, Ajinomoto, Solace Nutrition, Primus Pharmaceuticals, BioMarin Pharmaceutical, Danone SA and Galen Limited, etc. In 2022, the global top five players had a share approximately % in terms of revenue.

Report Includes:
This report presents an overview of global market for Medical Foods for Inborn Errors of Metabolism, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2018 - 2022, estimates for 2023, and projections of CAGR through 2029.
This report researches the key producers of Medical Foods for Inborn Errors of Metabolism, also provides the sales of main regions and countries. Highlights of the upcoming market potential for Medical Foods for Inborn Errors of Metabolism, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Medical Foods for Inborn Errors of Metabolism sales, revenue, market share and industry ranking of main manufacturers, data from 2018 to 2023. Identification of the major stakeholders in the global Medical Foods for Inborn Errors of Metabolism market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, sales, revenue, and price, from 2018 to 2029. Evaluation and forecast the market size for Medical Foods for Inborn Errors of Metabolism sales, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Nestlé, Abbott, Reckitt Benckiser Group, Ajinomoto, Solace Nutrition, Primus Pharmaceuticals, BioMarin Pharmaceutical, Danone SA and Galen Limited, etc.

By Company
Nestlé
Abbott
Reckitt Benckiser Group
Ajinomoto
Solace Nutrition
Primus Pharmaceuticals
BioMarin Pharmaceutical
Danone SA
Galen Limited
PKU-MDMIL
Segment by Type
Amino Acid
Glytactin with GMP
Amino Acid-Modified Infant Formula With Iron
Low Protein Food
Others
Segment by Application
Phenylketonuria (PKU)
Maple Syrup Urine Disease (MSUD)
Urea Cycle Disorders
Renal Disease
Others
Segment by Region
US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Middle East, Africa, Latin America
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of Medical Foods for Inborn Errors of Metabolism in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 3: Detailed analysis of Medical Foods for Inborn Errors of Metabolism manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: US & Canada (US & Canada) by type, by application and by country, sales and revenue for each segment.
Chapter 7: Europe by type, by application and by country, sales and revenue for each segment.
Chapter 8: China by type, by application sales and revenue for each segment.
Chapter 9: Asia (excluding China) by type, by application and by region, sales and revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by type, by application and by country, sales and revenue for each segment.
Chapter 11: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Medical Foods for Inborn Errors of Metabolism sales, revenue, price, gross margin, and recent development, etc.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: The main points and conclusions of the report.

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（医療/ヘルスケア）の最新刊レポート

QYResearch社の医薬・ヘルスケア分野での最新刊レポート

本レポートと同じKEY WORD（foods）の最新刊レポート

よくあるご質問

QYResearch社はどのような調査会社ですか?

QYリサーチ(QYResearch)は幅広い市場を対象に調査・レポート出版を行う、中国に本社をおく調査会社です。 QYResearchでは年間数百タイトルの調査レポートを出版しています。... もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

先天性代謝異常症用医療食品の世界市場インサイト、2029年までの予測

サマリー

目次

Summary

Table of Contents

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野（医療/ヘルスケア）の最新刊レポート

QYResearch社の医薬・ヘルスケア分野での最新刊レポート

本レポートと同じKEY WORD（foods）の最新刊レポート

よくあるご質問

QYResearch社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?